In mCRPC patients who had an initial response to Pluvicto but progress within 12 months, where do you position PSMA radioligand retreatment relative to other next-line systemic options in your sequencing strategy?

After Lu-PSMA therapy, we may consider taxane chemotherapy, Ra-223, ARPI, or clinical trials in addition to Lu-PSMA retreatment. Retreatment may be more heavily considered in patients with prior deep response to Lu-PSMA, high avidity on a repeat PSMA PET, and/or limited candidacy for other treatment...

For such a clinical situation, consideration of retreatment with PSMA radioligand therapy is evolving. There are currently phase II trials at UCLA Health (RE-LuPSMA) and in France (ReaLuP) for patients with a previous favorable response to Lu-PSMA that will assist in building the experience with suc...